Real-World Efficacy and Toxicity of Ipilimumab and Nivolumab as First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC) in a Subpopulation of Elderly and Poor Performance Status Patients
The use of ipi/nivo in mRCC demonstrated similar survival outcomes and toxicity in an older patient population. In patients with a poor performance status, it was associated with inferior OS and PFS. We believe that ipi/nivo is a reasonable treatment option for these patient populations, particularly in older patients.
Authors
- Jeffrey Graham (ORCID: https://orcid.org/0000-0002-8771-6815)
- Camilla Tajzler
- Simon Tanguay (ORCID: https://orcid.org/0000-0001-6947-304X)
- Naveen S. Basappa (ORCID: https://orcid.org/0000-0002-3163-9902)
- Rodney H. Breau (ORCID: https://orcid.org/0000-0003-2344-9022)
- Aly‐Khan A. Lalani (ORCID: https://orcid.org/0000-0002-9907-9112)
- Daniel Yick Chin Heng
- Noa Shani Shrem
- Frédéric Pouliot (ORCID: https://orcid.org/0000-0002-6651-1079)
- Bimal Bhindi (ORCID: https://orcid.org/0000-0002-6287-9837)
- Nazanin Fallah‐Rad
- Georg A. Bjarnason (ORCID: https://orcid.org/0000-0001-6903-5357)
- Denis Soulières (ORCID: https://orcid.org/0000-0002-1533-3815)
- Sunita Ghosh (ORCID: https://orcid.org/0000-0002-9763-5058)
- Ana-Alicia Beltran-Bless (ORCID: https://orcid.org/0000-0003-4880-8167)
- Lori Wood (ORCID: https://orcid.org/0000-0003-2405-0216)
- Antonio Finelli (ORCID: https://orcid.org/0000-0003-4032-6120)
- Christina Canil (ORCID: https://orcid.org/0000-0001-5657-6752)
- C. Kollmannsberger
Institutions
- Alberta Health Services (CA)
- Capital District Health Authority (CA)
- Sunnybrook Health Science Centre (CA)
- University Health Network (CA)
- University of Ottawa (CA)
- University of Alberta (CA)
- Juravinski Cancer Centre (CA)
- Queen Elizabeth II Health Sciences Centre (CA)
- Soroka Medical Center (IL)
- McGill University Health Centre (CA)
- Health Sciences Centre (CA)
- CancerCare Manitoba (CA)
- Centre hospitalier universitaire de Québec (CA)
- Centre Hospitalier de l’Université de Montréal (CA)
- McMaster University (CA)
Publication Details
- Journal
- Cancers
- Published
- 2025-02-04
- DOI
- https://doi.org/10.3390/cancers17030522
- Citations
- 5
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 7.59
Funders
- Amgen
- Pfizer
- AstraZeneca
- Advanced Accelerator Applications
- Seagen
- Eisai
- Astellas Pharma
- Ipsen
- Genentech
- EMD Serono